Skip to main content
NVDA-2.10%AAPL+2.69%GOOGL+0.24%MSFT+0.56%AMZN+0.12%TSM-0.81%SPCX+2.02%AVGO+0.03%META-0.22%TSLA-0.47%SKHY-3.57%MU-4.31%BRK-B-0.24%LLY+0.25%JPM-0.60%WMT+0.20%AMD-2.67%V-0.09%XOM+0.78%ASMLa-1.66%JNJ-0.19%INTC-4.47%MA-0.42%0700.HK-1.94%1398.HK+0.79%ORCL-2.97%ABBV+0.61%BAC-0.65%CSCO-0.91%CVX0.00%COST-0.01%KO+0.78%LRCX-4.62%CAT-1.46%AP2d-1.55%0005.HK-0.78%AMAT-2.16%UNH-0.23%HSBA.L-1.30%DELL-3.64%PG-0.05%MS-0.60%GE-0.47%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.05%HD-1.35%0939.HK+1.66%GS-0.76%NZDJPY-2.49%AUDJPY-1.75%CHFJPY-1.55%NZDCAD-1.40%EURNZD+1.34%GBPNZD+1.32%USDJPY-1.27%NZDUSD-1.25%EURJPY-1.20%GBPJPY-1.18%CADJPY-1.10%NZDCHF-0.97%USDZAR+0.89%USDNOK+0.82%EURZAR+0.79%USDSEK+0.77%AUDNZD+0.77%GBPZAR+0.74%EURNOK+0.72%AUDCAD-0.68%EURSEK+0.67%AUDDKK-0.60%CHFNOK+0.59%EURAUD+0.56%GBPAUD+0.55%USDTHB+0.54%CHFSEK+0.53%AUDUSD-0.49%AUDSGD-0.48%CADCHF+0.43%USDMXN+0.43%GBPTRY+0.41%NOKJPY-0.35%USDPLN+0.35%GBPCHF+0.35%EURCHF+0.34%GBPHKD+0.32%NZDSGD-0.31%USDCHF+0.29%GBPMXN-0.28%SGDJPY+0.25%EURPLN+0.25%USDSGD+0.21%AUDCHF-0.21%USDILS+0.16%USDCAD-0.15%AUDNOK+0.12%NZDMXN-0.12%PLNJPY+0.12%EURSGD+0.11%EURHKD-0.11%USDTRY+0.11%GBPCAD-0.10%USDDKK+0.10%EURCAD-0.10%EURCZK-0.08%USDCNH+0.08%GBPUSD+0.08%EURUSD+0.06%GBPSGD+0.06%USDCOP-0.04%CHFSGD-0.02%USDHKD+0.01%EURGBP+0.01%EURDKK0.00%EURCNH0.00%XPTUSD-5.22%UKOIL+4.94%USOIL+4.58%HG1-4.54%GAGUSD-4.20%XAGUSD-4.20%GAUUSD-0.80%XAUUSD-0.80%COTTON+0.67%S1+0.49%XNGUSD+0.48%COFFEE-0.46%BTCUSD-1.38%ETHUSD-0.57%USDTUSD-0.02%XRPUSD-2.75%SOLUSD-1.67%TRXUSDT+0.03%ZECUSDT-8.60%DOGEUSD-2.91%XMRUSDT-0.86%LINKUSD-1.49%XLMUSD-1.82%BCHUSDT-9.83%LTCUSD-1.56%UNIUSD-2.61%TONUSD+24.88%HBARUSDT-2.10%SUIUSD-3.76%TAOUSDT-4.65%AAVEUSD-2.57%DOTUSDT-2.67%ICPUSDT-1.78%ONDOUSDT-3.23%WLDUSDT-2.67%ATOMUSDT-3.51%ARBUSDT-0.87%JUPUSDT-4.25%INJUSDT-3.68%STXUSDT-4.16%FETUSDT-3.86%TIAUSDT-1.65%PYTHUSDT-1.33%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-3.02%WIFUSDT-5.38%OPUSDT-3.00%POLUSDT-4.56%IOTAUSDT-3.87%AXSUSDT-2.36%FARTCOINUSDT-4.03%EOSUSDT-2.91%DYDXUSDT-2.49%ORDIUSDT-1.37%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.10%AAPL+2.69%GOOGL+0.24%MSFT+0.56%AMZN+0.12%TSM-0.81%SPCX+2.02%AVGO+0.03%META-0.22%TSLA-0.47%SKHY-3.57%MU-4.31%BRK-B-0.24%LLY+0.25%JPM-0.60%WMT+0.20%AMD-2.67%V-0.09%XOM+0.78%ASMLa-1.66%JNJ-0.19%INTC-4.47%MA-0.42%0700.HK-1.94%1398.HK+0.79%ORCL-2.97%ABBV+0.61%BAC-0.65%CSCO-0.91%CVX0.00%COST-0.01%KO+0.78%LRCX-4.62%CAT-1.46%AP2d-1.55%0005.HK-0.78%AMAT-2.16%UNH-0.23%HSBA.L-1.30%DELL-3.64%PG-0.05%MS-0.60%GE-0.47%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.05%HD-1.35%0939.HK+1.66%GS-0.76%NZDJPY-2.49%AUDJPY-1.75%CHFJPY-1.55%NZDCAD-1.40%EURNZD+1.34%GBPNZD+1.32%USDJPY-1.27%NZDUSD-1.25%EURJPY-1.20%GBPJPY-1.18%CADJPY-1.10%NZDCHF-0.97%USDZAR+0.89%USDNOK+0.82%EURZAR+0.79%USDSEK+0.77%AUDNZD+0.77%GBPZAR+0.74%EURNOK+0.72%AUDCAD-0.68%EURSEK+0.67%AUDDKK-0.60%CHFNOK+0.59%EURAUD+0.56%GBPAUD+0.55%USDTHB+0.54%CHFSEK+0.53%AUDUSD-0.49%AUDSGD-0.48%CADCHF+0.43%USDMXN+0.43%GBPTRY+0.41%NOKJPY-0.35%USDPLN+0.35%GBPCHF+0.35%EURCHF+0.34%GBPHKD+0.32%NZDSGD-0.31%USDCHF+0.29%GBPMXN-0.28%SGDJPY+0.25%EURPLN+0.25%USDSGD+0.21%AUDCHF-0.21%USDILS+0.16%USDCAD-0.15%AUDNOK+0.12%NZDMXN-0.12%PLNJPY+0.12%EURSGD+0.11%EURHKD-0.11%USDTRY+0.11%GBPCAD-0.10%USDDKK+0.10%EURCAD-0.10%EURCZK-0.08%USDCNH+0.08%GBPUSD+0.08%EURUSD+0.06%GBPSGD+0.06%USDCOP-0.04%CHFSGD-0.02%USDHKD+0.01%EURGBP+0.01%EURDKK0.00%EURCNH0.00%XPTUSD-5.22%UKOIL+4.94%USOIL+4.58%HG1-4.54%GAGUSD-4.20%XAGUSD-4.20%GAUUSD-0.80%XAUUSD-0.80%COTTON+0.67%S1+0.49%XNGUSD+0.48%COFFEE-0.46%BTCUSD-1.38%ETHUSD-0.57%USDTUSD-0.02%XRPUSD-2.75%SOLUSD-1.67%TRXUSDT+0.03%ZECUSDT-8.60%DOGEUSD-2.91%XMRUSDT-0.86%LINKUSD-1.49%XLMUSD-1.82%BCHUSDT-9.83%LTCUSD-1.56%UNIUSD-2.61%TONUSD+24.88%HBARUSDT-2.10%SUIUSD-3.76%TAOUSDT-4.65%AAVEUSD-2.57%DOTUSDT-2.67%ICPUSDT-1.78%ONDOUSDT-3.23%WLDUSDT-2.67%ATOMUSDT-3.51%ARBUSDT-0.87%JUPUSDT-4.25%INJUSDT-3.68%STXUSDT-4.16%FETUSDT-3.86%TIAUSDT-1.65%PYTHUSDT-1.33%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-3.02%WIFUSDT-5.38%OPUSDT-3.00%POLUSDT-4.56%IOTAUSDT-3.87%AXSUSDT-2.36%FARTCOINUSDT-4.03%EOSUSDT-2.91%DYDXUSDT-2.49%ORDIUSDT-1.37%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%
EV

Evolus, Inc. (EOLS)

NASDAQ • Healthcare

$8.57
-$0.31 (-3.5%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$8.85
Previous Close$8.57
Day Range$8.51 - $9.05
Avg. Volume (3M)967.7K
Market Cap$517.2M
52 Week Range
$3.86$9.31
Next EarningsIn 55 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$84M100%
Gross Profitminus cost of goods$57.1M68%

In plain terms: out of every $100 in revenue, Evolus, Inc. currently loses $10.

Fundamentals & Financials

Revenue (TTM)
$316.4M
Net Income (TTM)
-$34.3M
EPS (TTM)
-$0.52
ROA (TTM)
-13.84%
Current Ratio
1.7

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-26.3%Q1 2026$0.04
+28.6%Q2 2026-$0.1
+122.3%Q3 2026$0.01
Next

Nov 4

in 55 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +122.3%

Evolus topped revenue expectations as sales rose 21.2% to about $84.1 million in the second fiscal quarter of 2026, reported August 5, 2026, with revenue of $84.1 million versus an $81.5 million estimate (+3.1%, topped) and growth still centered on its Jeuveau medical aesthetics franchise. Gross profit reached roughly $57.2 million, keeping gross margin at 68.0%, while operating results remained negative with operating income of about -$4.5 million and an operating margin of -5.4%. Net income narrowed to around -$8.1 million, a 53.0% improvement from a year ago, as the company lapped a larger loss in the prior-year quarter. Cash generation was also negative, with operating cash flow of about -$3.6 million. For the next period, consensus calls for EPS of -$0.03 on revenue of $77.8 million.

View full earnings history

About Evolus, Inc.

Evolus, Inc. develops and markets medical aesthetics treatments in the healthcare sector, centered on prescription products sold in the United States. The company, which trades on NASDAQ as EOLS, generated $297.2 million of revenue in FY2025 and operates within the specialty and generic drug manufacturing business.

Name
Evolus, Inc.
CEO
David Moatazedi
Website
www.evolus.com
Industry
Healthcare
Year Founded
2012
Employees
353

Today's Snapshot

AI-generated

So far today, EOLS is trading 7.9% lower at 7.89, while its sector was flat.

Trading Volume

Below 10d avg (914.9K)

355.5K

vs S&P 500 Today

Strong Underperformance

-7.32%

Updated: September 10, 2026 at 16:45 UTC

Technical Indicators

3 Buy3 Neutral2 Sell
EOLS registers a buy stance underpinned by a strong ADX that indicates a well-established trend and by the price remaining above longer-term moving averages, showing longer-term bullish support. However, short-term averages are trading above the current price and short-term momentum is weak, with an oversold Williams %R suggesting recent selling pressure. MACD is neutral and volatility is modest, while on-balance volume is soft, implying limited buying conviction on pullbacks. Technical takeaway: Buy — the strong trend and support from longer-term averages favor bulls despite short-term weakness and thin volume.
All signals
  • EMA (5 indicators)$6.55 - $8.75
    Buy
  • RSI (14)50.10
    Neutral
  • Stochastic %K (14, 3, 3)31.87
    Neutral
  • MACD Level (12, 26)0.41
    Neutral

Peers & Related Assets

SLDBSolid Biosciences Inc.
$9.54-3.9%
CBLLCeriBell, Inc.
$24.41+0.4%
NGNENeurogene Inc.
$37.88-0.7%
KIDSOrthoPediatrics Corp.
$21.68-2.4%
TMCITreace Medical Concepts, Inc.
$4.53-2.2%
QSIQuantum-Si incorporated
$0.75-1.3%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.